<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58782">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02013934</url>
  </required_header>
  <id_info>
    <org_study_id>PAB/011013</org_study_id>
    <nct_id>NCT02013934</nct_id>
  </id_info>
  <brief_title>Probiotics in Prevention of Common Cold</brief_title>
  <official_title>Benefit and Tolerability of a Probiotic Product in Subjects With Increased Susceptibility to Common Cold</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Probi AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Probi AB</source>
  <oversight_info>
    <authority>Germany: Charité - Universitätsmedizin Berlin Ethikkommission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the benefit and tolerability of a probiotic product
      in subjects with increased susceptibility to common cold.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Severity of cold symptoms</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Severity of cold symptoms based on the questionnaire WURSS-21 during the cold episodes throughout the study period, in comparison between verum and placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of common cold episodes</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Viral Infections of the Upper Respiratory Tract</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males and females

          -  age 18-70 years

          -  increased risk for common cold (at least 4 episodes within 12 months)

          -  commitment to adhere to former diet and physical activity

          -  commitment not to use any products that may influence the study outcome (e.g. immune
             suppressants/immune stimulants, including paramedication such as e.g. Echinacea,
             analgesics/anti-rheumatics, anti-phlogistics, antitussives/expectorants, influenza
             remedies, mouth or throat therapeutics, decongestants, antibiotics,
             anti-histaminergic drugs, probiotics) during the study (except for rescue medication,
             see 7.5)

          -  women of child-bearing potential have to agree to use appropriate birth control
             methods Written consent of the subject to participate is a prerequisite for study
             participation.

        Exclusion Criteria:

          -  acute / chronic upper / lower airways disease

          -  chronic cough of any origin

          -  any allergic reaction that may influence the study outcome (e.g. acute/chronic
             rhinitis)

          -  history of nasal reconstructive surgery

          -  presence of nasal ulcers or nasal polyps

          -  severe nasal septum deviation or other condition that could cause nasal obstruction

          -  congenital or acquired immunodeficiency disease (e.g. HIV infection)

          -  Bechterew's disease

          -  body temperature above 37.5°C

          -  suspected swine flu or influenza

          -  vaccination with a vaccine containing an adjuvant within 3 months prior to study
             start and during the study

          -  vaccination with a vaccine not containing an adjuvant within 6 weeks prior to study
             start and during the study

          -  stomach/gastrointestinal diseases

          -  serious organ or systemic diseases

          -  sleep disorder

          -  psychiatric disorders

          -  known sensitivity to the ingredients of the investigational product

          -  regular intake of products that may influence the study outcome (e.g. immune
             suppressants/immune stimulants, including paramedication such as e.g. Echinacea,
             analgesics/anti-rheumatics, anti-phlogistics, antitussives/expectorants, influenza
             remedies, mouth or throat therapeutics, decongestants, antibiotics,
             anti-histaminergic drugs, probiotics) within the last 4 weeks prior to study start

          -  habitual usage of nasal drops/spray

          -  pregnancy or nursing

          -  alcohol / drug abuse

          -  simultaneous participation in another clinical trial or participation in a clinical
             trial within the last 30 days

          -  insufficient compliance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Irini Lazou Ahrén, PhD</last_name>
    <phone>+46 46 286 89 22</phone>
    <email>ila@probi.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>A&amp;R</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Schaudt</last_name>
      <email>mschaudt@analyze-realize.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 11, 2013</lastchanged_date>
  <firstreceived_date>December 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Common Cold</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
